Propanc Biopharma Updates on Corporate Progress and Reports Half-Yearly 2025/26 Results

Propanc Biopharma announces corporate updates and reports half-yearly 2025/26 results. The company filed four provisional patent applications to strengthen global protection for its breakthrough proenzyme formulations and published findings on the impact of proenzymes on pancreatic ductal adenocarcinoma fibroblasts in a peer-reviewed journal. Propanc also entered into a $100 million private placement facility to accelerate clinical development and reported total assets of $15.11 million and net cash from financing activities of $3.49 million.